Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAGE: Anastrozole vs. Tamoxifen with Goserelin in Premenopausal Breast Cancer
NCT00605267Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2007
- Primary completion
- Nov 2009
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of anastrozole in breast cancer (2 arms), sponsored by AstraZeneca. Primary endpoints: Best Overall Response Rate (Calliper) at 24 weeks, Best Overall Response Rate (Ultrasound) at 24 weeks and 1 more. Started Oct 2007; status: completed.
02
Drugs
anastrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00605267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00605267.